Skip to main content
. 2012 Jan 25;119(12):2768–2777. doi: 10.1182/blood-2011-05-353201

Figure 1.

Figure 1

Human hematopoietic engraftment is enhanced in hSCF Tg NSG recipients. (A) hSCF Tg NSG recipients developed progressive anemia as evidenced by reduced hemoglobin concentration compared with non-Tg NSG mice transplanted with human HSCs from the same donor source. (B) Human CD45+ chimerism was analyzed over time in PB of hSCF Tg and non-Tg NSG recipients. (C) Representative flow cytometric contour plots demonstrating the presence of human CD45+ cells, CD19+ B cells, CD33+ myeloid cells, CD3+ T cells, and CD56+CD3− NK cells in recipient BM. (D) At the time of death, engraftment levels of human CD45+ cells in the BM, spleen, and PB of hSCF Tg NSG recipients were significantly higher compared with non-Tg NSG controls (BM: hSCF Tg n = 21, non-Tg n = 13, P < .0001; spleen: hSCF Tg n = 21, non-Tg n = 13, P = .0065; PB: hSCF Tg n = 21, non-Tg n = 13, P < .0001). (E) In hSCF Tg NSG recipient BM, significantly greater human CD33+ myeloid lineage development was observed (hSCF Tg n = 21, non-Tg n = 13, P = .0002).